Fidelity Investments
SPRO icon

Fidelity Investments’s Spero Therapeutics SPRO Stock Holding History

Fidelity Investments’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663 Buy
+300
New +$785 ﹤0.01% 5286
2025
Q4 		– Sell
-550
Closed -$1.03K – 5582
2025
Q3 		$1.03K Buy
+550
New +$1.21K ﹤0.01% 5013
2025
Q2 		– Sell
-5,056
Closed -$3.64K – 5493
2025
Q1 		$3.64K Buy
5,056
+767
+18% +$647 ﹤0.01% 4782
2024
Q4 		$4.42K Buy
4,289
+1,150
+37% +$1.37K ﹤0.01% 4688
2024
Q3 		$4.21K Buy
3,139
+250
+9% +$335 ﹤0.01% 4660
2024
Q2 		$3.76K Buy
2,889
+500
+21% +$754 ﹤0.01% 4621
2024
Q1 		$4.11K Buy
2,389
+2,200
+1,164% +$3.45K ﹤0.01% 4565
2023
Q4 		$278 Buy
+189
New +$225 ﹤0.01% 4853
2023
Q3 		– Sell
-4
Closed -$6 – 5500
2023
Q2 		$6 Buy
+4
New +$7 ﹤0.01% 5308
2022
Q3 		– Sell
-4,120
Closed -$3K – 5363
2022
Q2 		$3K Buy
4,120
+4,017
+3,900% +$11.7K ﹤0.01% 4493
2022
Q1 		$1K Buy
+103
New +$1.05K ﹤0.01% 4845
2021
Q2 		– Sell
-8,552
Closed -$126K – 4826
2021
Q1 		$126K Hold
8,552
– – ﹤0.01% 2892
2020
Q4 		$166K Sell
8,552
-2,200
-20% -$34.3K ﹤0.01% 2811
2020
Q3 		$120K Sell
10,752
-30,900
-74% -$366K ﹤0.01% 2766
2020
Q2 		$564K Sell
41,652
-57,300
-58% -$643K ﹤0.01% 2497
2020
Q1 		$800K Hold
98,952
– – ﹤0.01% 2367
2019
Q4 		$951K Sell
98,952
-71,636
-42% -$773K ﹤0.01% 2413
2019
Q3 		$1.81M Sell
170,588
-58,364
-25% -$615K ﹤0.01% 2291
2019
Q2 		$2.63M Sell
228,952
-160,300
-41% -$1.93M ﹤0.01% 2261
2019
Q1 		$4.99M Sell
389,252
-99,300
-20% -$1.05M ﹤0.01% 2082
2018
Q4 		$3M Sell
488,552
-129,654
-21% -$1.05M ﹤0.01% 2185
2018
Q3 		$6.5M Sell
618,206
-181,794
-23% -$2.11M ﹤0.01% 2066
2018
Q2 		$11.7M Hold
800,000
– – ﹤0.01% 1899
2018
Q1 		$11.4M Hold
800,000
– – ﹤0.01% 1925
2017
Q4 		$9.4M Buy
+800,000
New +$9.82M ﹤0.01% 1973

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments's SPRO Position: Q2 2026 in Review

Fidelity Investments opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 300 shares worth $663. The stake represents ﹤0.01% of the portfolio and ranks #5286 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in SPRO as recently as Q3 2025.

Fidelity Investments first reported a position in SPRO in Q4 2017 and has held it in 25 quarters since. The position peaked at $11.7M in Q2 2018. 59 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Fidelity Investments held 300 shares of Spero Therapeutics worth $663 as of Q2 2026.
  • Spero Therapeutics was a new Fidelity Investments position in Q2 2026.
  • Spero Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5286 holding.
  • Fidelity Investments first reported a position in Spero Therapeutics in Q4 2017 and has held it in 25 quarters since.
  • Fidelity Investments's Spero Therapeutics position peaked at $11.7M in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.